R1 Therapeutics expands Series A financing to $80.5 million with new investment from Samsara BioCapital. The funds will advance their Phase 2b program for hyperphosphatemia in patients with chronic kidney disease.
Amount Raised
$80.5 Million
Round Type
Series A
Investors
Description
R1 Therapeutics, a biopharmaceutical company focused on kidney disease therapies, has expanded its Series A financing to $80.5 million. This expansion includes new investment from Samsara BioCapital, joining other notable investors. The raised funds will support the development of R1's lead asset, AP306, in a global Phase 2b trial. The trial aims to address hyperphosphatemia in patients on dialysis, with topline data expected in early 2027.
Quick answer
R1 Therapeutics raised $80.5 Million in a Series A round, dated September 30, 2026. Investors: U.S. Renal Care, SNMA Capital, Curie.Bio, F Prime, DaVita Venture Group, Abingworth and Samsara Biocapital.
- How much did R1 Therapeutics raise?
- R1 Therapeutics raised $80.5 Million in a Series A round on September 30, 2026.
- Who invested in R1 Therapeutics?
- U.S. Renal Care, SNMA Capital, Curie.Bio, F Prime, DaVita Venture Group, Abingworth and Samsara Biocapital are named as investors in this round.
- What does R1 Therapeutics do?
- R1 Therapeutics is a biotechnology company focused on developing innovative therapeutics.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as R1 Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- VectorY raised $83M on November 11, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
Who to call at R1 Therapeutics, and when
A new round usually means R1 Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day R1 Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at R1 Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at R1 Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment R1 Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansR1 Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.